CAMBRIDGE, Mass.--(BUSINESS WIRE)--Incendia Therapeutics, a precision oncology company discovering and developing a novel class of therapies that reprogram the tumor microenvironment (TME), today ...
Discoidin domain receptor tyrosine kinase 1 (DDR1) contributes to tumor progression by promoting the alignment and densification of collagen fibers within the extracellular matrix (ECM), thereby ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results